Press Releases

Important Update: NBTS Events and COVID-19 (Coronavirus) Last Update: March 9, 2020 National Brain Tumor Society (NBTS) understands that many of our supporters may have questions and concerns related to ongoing news reports about the spread of the novel coronavirus, known as COVID-19. At this time, the U.S. Centers for Disease Control and Prevention (CDC) risk assessment states that: “For most people, […] March 10, 2020

Update on Patient Prescription Assistance for Temodar (Temozolomide) A chemotherapy drug known as Temodar (generic name: temozolomide) is part of the standard of care treatment for many patients with malignant brain tumors. Temodar/temozolomide is one of just a small handful of FDA-approved treatments for brain tumor patients and is the backbone medication for a significant proportion of individuals diagnosed with gliomas, including glioblastoma, […] February 4, 2020

National Brain Tumor Society Provides Funding for the Development Novel Therapy with Potential to Treat Adult and Pediatric Brain Cancers Leading brain tumor patient advocacy organization commits to providing more than $200,000 to support a phase II clinical trial of ONC201 National Brain Tumor Society (NBTS), a leader in brain tumor patient advocacy, today announces a commitment of at least $200,000 to support a forthcoming phase II clinical trial of the investigational therapy, ONC201, with […] January 27, 2020

$500,000 Awarded to Advance Brain Cancer Research at 10 Leading Cancer Research Institutes Through Patient-Nonprofit Partnership Sharpe-NBTS Brain Cancer Awards provide $50,000 infusions of funding for innovative brain cancer R&D efforts National Brain Tumor Society (NBTS) announced the Sharpe-NBTS Brain Cancer Research Awards program will invest $500,000 in cutting-edge brain cancer studies at 10 leading scientific laboratories across the United States. Each lab will receive $25,000 for a period of two […] August 24, 2019

National Brain Tumor Society Applauds Medicare’s Coverage Decision for Tumor Treatment Field Therapy On the heels of the first-ever Glioblastoma Awareness Day (#GBMDay) in the United States, we’ve received some terrific news for patients that is a direct result of the brain tumor community’s advocacy efforts. As you know, there are only four drugs and one device currently approved by the U.S. Food and Drug Administration (FDA) for […] July 18, 2019